Real-world efficacy and safety of Erenumab: a prospective study of 80 patients in a specialized headache center

Anti-CGRP monoclonal antibodies and particularly Erenumab become the first migraine-specific treatment and have demonstrated high efficacy and safety in the randomized clinical trials.Aim. The aim of this study is the prospective evaluation of the efficacy and safety of Erenumab in patients with episodic migraine (EM) and chronic migraine (CM).Material and мethods. We recruited patients aged 18–85 diagnosed with EM and CM according to the International Classification of Headache Disorders, 3rd edition. All patients were from November 2020 to December 2021. Demographic data, history of migraine and previous migraine treatment were collected for each patient. All patients filled out scales and questionnaires, headache frequency dynamics was followed up monthly with headache diaries.Results. After three months of treatment reduction marked reduction of headache frequency was observed, and 53.5% of patients became ≥ 50% responders. After six months of treatment a further increase in the effect was observed: 57% of patients had at least a two-fold reduction in headache frequency, 74% of patients became ≥ 30% responders. Constipation was observed in 3.8% of patients.Conclusion. Erenumab is safe and effective in the treatment of moderate- and high-frequency EM, CM and medication-overuse headache.

[1]  E. V. Ekusheva,et al.  The use of the monoclonal antibody Erenumab in patients with chronic migraine in real clinical experience , 2021, Russian neurological journal.

[2]  G. Terwindt,et al.  Treatment with the monoclonal calcitonin gene‐related peptide receptor antibody erenumab: A real‐life study , 2021, European Journal of Neurology.

[3]  A. Straube,et al.  Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in Germany , 2021, The Journal of Headache and Pain.

[4]  M. Filippi,et al.  Erenumab in the prevention of high‐frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real‐life study , 2020, Headache.

[5]  P. Cortelli,et al.  Erenumab in 159 high frequency and chronic migraine patients: real-life results from the Bologna Headache Center , 2020, Neurological Sciences.

[6]  S. Sacco,et al.  Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy , 2020, The Journal of Headache and Pain.

[7]  S. Sacco,et al.  The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal , 2019, The journal of headache and pain.

[8]  P. Barbanti,et al.  Erenumab: from scientific evidence to clinical practice—the first Italian real-life data , 2019, Neurological Sciences.

[9]  S. Tepper CGRP and headache: a brief review , 2019, Neurological Sciences.

[10]  S. Sacco,et al.  European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention , 2019, The Journal of Headache and Pain.

[11]  P. Martelletti Erenumab is effective in reducing migraine frequency and improving physical functioning , 2018, BMJ Evidence-Based Medicine.

[12]  D. Dodick,et al.  ARISE: A Phase 3 randomized trial of erenumab for episodic migraine , 2018, Cephalalgia : an international journal of headache.

[13]  M. Naprienko,et al.  Strategies for Improving the Efficacy of Treatment of Chronic Migraine , 2017, Neuroscience and Behavioral Physiology.

[14]  L. Bloudek,et al.  Systematic Review of Migraine Prophylaxis Adherence and Persistence , 2014, Journal of managed care pharmacy : JMCP.

[15]  R. Ohrbach,et al.  The International Classification of Headache Disorders, 3rd edition (beta version) , 2013, Cephalalgia : an international journal of headache.

[16]  David Cella,et al.  Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. , 2008, The journal of pain : official journal of the American Pain Society.